Department of Internal Medicine Division of Medical Oncology, Marmara University School of Medicine, Marmara University Pendik Education and Research Hospital, Istanbul, Turkey.
Department of Internal Medicine Division of Medical Oncology, Marmara University School of Medicine, Marmara University Pendik Education and Research Hospital, Istanbul, Turkey.
Neurocirugia (Astur : Engl Ed). 2022 Jan-Feb;33(1):15-21. doi: 10.1016/j.neucie.2020.11.004.
Primary brain tumors are relatively rare malignancy, with high-grade gliomas (glioblastoma multiforme and anaplastic gliomas) are the most common types. We aimed to evaluate the prognostic value of Prognostic Nutritional Index (PNI), which is calculated by lymphocyte count and albumin, in recurrent glioblastoma patients treated with systemic treatment.
Data of 64 patients with recurrent glioblastoma who received systemic treatment and followed in our clinic between 2012 and 2018 was retrospectively collected and analyzed. PNI was calculated as: [(10×serum albumin (g/dL))+(0.005×total lymphocyte count)]. Patients were categorized according to the median PNI value. We investigated the prognostic role of PNI groups, and survival outcomes.
Median value of PNI was 45.7, and median follow-up duration was 9 months (1-68 months). Median overall survival (OS) was 7.9 months (95%CI: 5.5-10.4). Median OS was significantly longer in patients with PNI>45.7 compared to patients with PNI≤45.7 (13.9 months (95%CI: 10.5-17.4), and 4.6 months (95%CI: 2.5-6.8), p<0.001, respectively). In multivariate analysis, PNI was found to be an independent prognostic factor for OS [HR:0.41 (95%CI:0.22-0.74), p=0.03)].
In our study, the PNI was found to be an independent prognostic biomarker in patients with recurrent glioblastoma, but further prospective trials are necessary to validate its prognostic role.
原发性脑肿瘤相对罕见，恶性程度较高，其中高级别胶质瘤（多形性胶质母细胞瘤和间变性胶质瘤）最为常见。我们旨在评估预后营养指数（PNI）在接受系统治疗的复发性胶质母细胞瘤患者中的预后价值，PNI 由淋巴细胞计数和白蛋白计算得出。
回顾性收集并分析了 2012 年至 2018 年间在我院接受系统治疗并随访的 64 例复发性胶质母细胞瘤患者的数据。PNI 计算方法为：[(10×血清白蛋白（g/dL）)]+（0.005×总淋巴细胞计数）。根据 PNI 的中位数将患者分为两组。我们研究了 PNI 组的预后作用和生存结果。
PNI 的中位数为 45.7，中位随访时间为 9 个月（1-68 个月）。中位总生存期（OS）为 7.9 个月（95%CI：5.5-10.4）。PNI>45.7 的患者 OS 明显长于 PNI≤45.7 的患者（13.9 个月（95%CI：10.5-17.4）和 4.6 个月（95%CI：2.5-6.8），p<0.001）。多变量分析显示，PNI 是 OS 的独立预后因素[HR：0.41（95%CI：0.22-0.74），p=0.03]。
在我们的研究中，PNI 被发现是复发性胶质母细胞瘤患者的独立预后生物标志物，但需要进一步的前瞻性试验来验证其预后作用。
